Saul Faust to Intention to Treat Analysis
This is a "connection" page, showing publications Saul Faust has written about Intention to Treat Analysis.
Connection Strength
0.049
-
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet. 2021 09 04; 398(10303):856-869.
Score: 0.049